The effectiveness of Tuina in relieving pain, negative emotions, and disability in knee osteoarthritis: A randomized controlled trial.

Autores
Categoría Estudio primario
RevistaPain medicine (Malden, Mass.)
Año 2023
Cargando información sobre las referencias

OBJECTIVE:

To evaluate the effectiveness of Tuina in relieving the pain, negative emotions, and disability of patients with knee osteoarthritis (KOA).

DESIGN:

Single-center, parallel, randomized controlled trial.

SETTING:

Shanghai Guanghua Integrated Chinese and Western Medicine Hospital, Shanghai, China. Subjects: Adult patients with KOA who were able to speak Chinese and self-report symptoms were eligible.

METHODS:

A total of 104 patients were randomly allocated to receive the 6-week treatment of Tuina (Tuina group) or celecoxib (celecoxib group). Data on pain, negative emotions, and disability were collected at baseline, at week 2, 4, and 6, and follow-up (1 month after the last treatment). The primary outcomes were the pressure pain thresholds. The secondary outcomes were: (1) numerical rating scale at rest and with movement; (2) Hamilton Anxiety Scale; (3) Hamilton Depression Scale; (4) Western Ontario and McMaster Universities Osteoarthritis Index; and (5) clinical effective rate. The adverse events of the trial were evaluated.

RESULTS:

In total, 99 patients completed the follow-up. Generalized linear mixed models were constructed to analyse the between-group differences. Statistically significant differences were found in the interaction effects (P < .05). In evaluating the group effect, statistical differences were found at week 6 and follow-up (P < .05). Further, all variables showed a time effect (P < .05). A statistical difference in the clinical effective rate was found between the Tuina and celecoxib groups (P < .05).

CONCLUSIONS:

Tuina produced superior effects for pain, negative emotions, and disability over time, as compared to celecoxib in patients with KOA. (PsycInfo Database Record (c) 2024 APA, all rights reserved)
Epistemonikos ID: 4f4ac46cf26440db3eb5557b0a22e5121ea68c92
First added on: May 26, 2023